Abstract 111P
Background
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors (ICIs). In this comparative study, we aimed to compare incidence, clinical characteristics and outcomes of irLI between patients receiving ICIs for HCC versus other solid tumour indications.
Methods
Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line Atezolizumab+Bevacizumab from AB-real study and a non-HCC cohort, including 459 patients treated with first-line ICI therapy from INVIDIa-2 multicentre study. IrLI was defined as treatment-related increase of transaminases levels after exclusion of alternative aetiologies of liver injury. Incidence of irLI was adjusted for the duration of treatment exposure.
Results
In HCC patients, incidence of any-grade irLI was 11.4% over a median treatment exposure of 4.4 months (95%CI 3.7-5.2), compared to 2.6% in INVIDIa-2 cohort over a median treatment exposure of 12.4 months (95%CI 11.1-14.0). Exposure-adjusted incidence of any-grade irLI was 22.1 per 100-Patient-years (PY) in HCC patients and 2.1 per 100-PY in non-HCC patients (p<0.001), with median time to irLI of 1.4 in HCC and 4.7 months in non-HCC patients, respectively. Among patients who developed irLI, systemic corticosteroids were administered in 16.3% of HCC and in 75.0% of non-HCC patients (p<0.001) and irLI resolution was observed in 72.1% and 58.3%, respectively (p=0.362). In HCC patients, rates of hepatic decompensation and treatment discontinuation due to irLI were 7%. In both cohorts, no fatal irLI events occurred. Development of grade 1-2 irLI was associated with improved overall survival in HCC patients only (HR 0.53, 95%CI 0.29-0.96).
Conclusions
Despite higher incidence and earlier onset in patients with HCC, IrLI is characterised by high rates of remission, low requirement for corticosteroid therapy and low risk of decompensation compared to other solid tumours. Hepatotoxicity leads to discontinuation in 7% of patients with HCC and does not negatively affect oncological outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Celsa: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, AstraZeneca, MSD. G. Cabibbo: Financial Interests, Personal, Advisory Board: Bayer, Eisai, Ipsen, MSD, AstraZeneca, Roche. T.U. Marron: Financial Interests, Personal, Advisory Board: Rockfeller University, Regeneron, AbbVie, Merck, Bristol Myers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, DrenBio, GlenMark, Simcere, Surface, G1 Therapeutics, NGMBio, DBV Technologies, Arcus, Astellas; Financial Interests, Personal, Research Grant: Regeneron, Bristo-Myers Squibb, Merck, Boehringer Ingelheim. A. Saeed: Financial Interests, Personal, Research Grant: AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Five Prime Therapeutics, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, BioNtech; Financial Interests, Personal, Advisory Board: Merck, AstraZeneca, Bristol Myers Squibb, Exelixis, Taiho, Pfizer. M. Pinter: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Eisai, Ipsen, Lilly, MSD, Roche; Financial Interests, Personal, Non remunerated activity: Bayer, Bristol Myers Squibb. A. Pillai: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai, Exelixis, Genentech/Roche, AstraZeneca, Replimune. M. Schoenlein: Financial Interests, Personal, Other: Janssen, Ipsen, BMS, Astellas, Pfizer; Financial Interests, Personal, Speaker, Consultant, Advisor: Janssen. J. von Felden: Financial Interests, Personal, Advisory Board: Roche. P.R. Galle: Financial Interests, Personal, Advisory Board: Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Lilly, Merck Sharp and Dome, Roche, Sirtex; Financial Interests, Personal, Research Funding: Bayer, Roche; Financial Interests, Personal, Expert Testimony: Lilly; Financial Interests, Personal, Other: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Lilly, Roche. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Lilly, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, Elevar Therapeutics, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Bayer, BMS, Incyte, Ipsen, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene, Zymeworks; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Coordinating PI, European PI: AstraZeneca; Non-Financial Interests, Personal, Leadership Role, Treasurer: ILCA; Non-Financial Interests, Personal, Leadership Role, Co-chair: EORTC GITCG HB/NET Task Force; Non-Financial Interests, Personal, Other, Special Expert Clinical Trials Europe: NCI HB Task Force. A. Singal: Financial Interests, Personal, Advisory Board: Genentech, AstraZeneca, Eisai, Bayer, Exelixis, BMS, Roche, Glycotest, Exact Sciences, FujiFilm Medical Sciences, GRAIL. H. Chon: Financial Interests, Personal, Advisory Board: Eisai, Roche, Bayer, ONO, MSD, BMS, Celgene, Sanofi, Servier, AstraZeneca, Sillajen, Menarini, GreenCross Cell. M. Bersanelli: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Ipsen; Financial Interests, Personal, Other, Case report with copyright transfert: Pierre Fabre; Financial Interests, Institutional, Other, Research funding: Roche, Seqirus, Pfizer, Novartis; Financial Interests, Personal, Writing Engagement: Pierre Fabre, Sciclone Pharmaceuticals; Financial Interests, Personal, Invited Speaker: MSD, Novartis; Financial Interests, Institutional, Local PI: Pfizer; Non-Financial Interests, Personal, Product Samples, congresso grant and accomodation: Pierre Fabre. A. Cortellini: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, OncoC4, Ardelis Health, Access Infinity, AlphaSight; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eisai, Pierre Fabre; Financial Interests, Personal, Writing Engagement: MSD, BMS. D.J. Pinato: Financial Interests, Personal, Advisory Board: Mina Therapeutics, Eisai, Exact Sciences, MURSLA, H3B, DaVolterra, AstraZeneca, Bayer Healthcare; Financial Interests, Personal, Invited Speaker: BMS, IPSEN, Roche; Financial Interests, Personal, Other, Editor in Chief role: Wiley; Financial Interests, Institutional, Research Grant: BMS, MSD; Non-Financial Interests, Personal, Principal Investigator: Incyte, H3B, Starpharma, Roche, Ribon Therapeutics, Turning Point Therapeutics, Apollomics; Non-Financial Interests, Personal, Other, Charity Trustee: Cancer Treatment and Research Trust. All other authors have declared no conflicts of interest.
Resources from the same session
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display